X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (441) 441
Publication (26) 26
Book Review (8) 8
Newspaper Article (4) 4
Newsletter (3) 3
Book Chapter (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pemetrexed (386) 386
humans (318) 318
oncology (264) 264
index medicus (241) 241
guanine - analogs & derivatives (233) 233
chemotherapy (191) 191
female (185) 185
male (174) 174
middle aged (153) 153
aged (148) 148
cancer (138) 138
lung neoplasms - drug therapy (132) 132
glutamates - administration & dosage (129) 129
guanine - administration & dosage (129) 129
pharmacology & pharmacy (122) 122
adult (118) 118
carcinoma, non-small-cell lung - drug therapy (109) 109
antineoplastic combined chemotherapy protocols - therapeutic use (105) 105
lung cancer (88) 88
cisplatin (83) 83
glutamates - adverse effects (79) 79
guanine - adverse effects (79) 79
glutamates - pharmacokinetics (78) 78
guanine - pharmacokinetics (78) 78
lung cancer, non-small cell (77) 77
treatment outcome (73) 73
gemcitabine (72) 72
research (71) 71
glutamates - therapeutic use (68) 68
guanine - therapeutic use (68) 68
care and treatment (67) 67
lung neoplasms - pathology (67) 67
animals (66) 66
antineoplastic combined chemotherapy protocols - adverse effects (66) 66
medicine & public health (66) 66
antineoplastic agents - therapeutic use (63) 63
cell lung-cancer (62) 62
carboplatin (58) 58
cancer therapies (57) 57
glutamates - pharmacology (56) 56
guanine - pharmacology (56) 56
drug therapy (55) 55
mesothelioma (55) 55
neoplasms - drug therapy (55) 55
dose-response relationship, drug (54) 54
carcinoma, non-small-cell lung - pathology (53) 53
pharmacokinetics (53) 53
non-small cell lung cancer (52) 52
thymidylate synthase (52) 52
malignant pleural mesothelioma (48) 48
antimitotic agents (46) 46
antineoplastic agents (46) 46
cisplatin - administration & dosage (46) 46
antineoplastic combined chemotherapy protocols - administration & dosage (45) 45
cell line, tumor (45) 45
multitargeted antifolate (45) 45
pemetrexed - administration & dosage (45) 45
pharmacology/toxicology (45) 45
combination (44) 44
neoplasm staging (44) 44
aged, 80 and over (43) 43
clinical trials (43) 43
therapy (43) 43
analysis (42) 42
mesothelioma - drug therapy (42) 42
solid tumors (42) 42
toxicity (41) 41
tumors (41) 41
antineoplastic agents - administration & dosage (40) 40
antineoplastic combined chemotherapy protocols - pharmacokinetics (40) 40
antineoplastic agents - adverse effects (39) 39
antineoplastic agents - pharmacokinetics (39) 39
cancer research (38) 38
ly231514 (38) 38
pharmacology (38) 38
metastasis (37) 37
trial (37) 37
antineoplastic agents - pharmacology (36) 36
drug administration schedule (36) 36
health aspects (36) 36
maximum tolerated dose (35) 35
nsclc (35) 35
deoxycytidine - analogs & derivatives (33) 33
phase-ii trial (33) 33
methotrexate (32) 32
multitargeted antifolate ly231514 (32) 32
antifolate (31) 31
dosage and administration (31) 31
folic acid antagonists - pharmacokinetics (31) 31
patients (30) 30
disease-free survival (29) 29
folic acid (29) 29
mice (28) 28
adenocarcinoma - drug therapy (27) 27
antimetabolites, antineoplastic - therapeutic use (27) 27
development and progression (27) 27
docetaxel (27) 27
folic-acid (27) 27
neutropenia - chemically induced (27) 27
oncology, experimental (27) 27
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Cancer, ISSN 0959-8049, 11/2017, Volume 86, pp. 186 - 196
The phosphatidylinositol 3-kinase (PI3K) pathway is a potential therapeutic target in non–small cell lung cancer (NSCLC). This study aimed to evaluate the... 
First-line NSCLC | Metastatic NSCLC | Non–small cell lung | Paclitaxel | Carboplatin | Phosphatidylinositol 3-kinase | Pemetrexed | Cisplatin | Bevacizumab | Front-line NSCLC | SUBTYPES | PI3K INHIBITORS | KINASE | SENSITIVITY | OPPORTUNITIES | LESSONS | GDC-0941 | POTENT | PRECLINICAL MODELS | PATHWAY | Non-small cell lung | ONCOLOGY | Lung Neoplasms - drug therapy | Bevacizumab - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Phosphatidylinositol 3-Kinases - metabolism | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Cisplatin - administration & dosage | Carboplatin - adverse effects | Drug Dosage Calculations | Aged, 80 and over | Adult | Female | Paclitaxel - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Protein Kinase Inhibitors - pharmacokinetics | Lung Neoplasms - enzymology | Bevacizumab - administration & dosage | Drug Administration Schedule | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Treatment Outcome | Sulfonamides - pharmacokinetics | Protein Kinase Inhibitors - administration & dosage | Indazoles - pharmacokinetics | Pemetrexed - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Pemetrexed - administration & dosage | Sulfonamides - adverse effects | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Indazoles - adverse effects | Neoplasm Staging | Sulfonamides - administration & dosage | Antimitotic agents | Care and treatment | Safety and security measures | Lung cancer, Small cell | Metastasis | Lung cancer, Non-small cell | Antineoplastic agents
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2013, Volume 31, Issue 27, pp. 3327 - 3334
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2016, Volume 34, Issue 5, pp. 625 - 635
Introduction LY2603618 is a selective inhibitor of checkpoint kinase 1 (CHK1) protein kinase, a key regulator of the DNA damage checkpoint, and is predicted to... 
Medicine & Public Health | CHK1 protein kinase inhibitor | Non-small cell lung cancer | Oncology | LY2603618 | Pharmacology/Toxicology | Pharmacokinetics | p53 | CHECKPOINT KINASE 1 | CRITERIA | NETWORK | ADVANCED SOLID TUMORS | DNA-DAMAGE | GEMCITABINE | TRIAL | DOSE-ESCALATION | THERAPY | ONCOLOGY | PHARMACOLOGY & PHARMACY | Lung Neoplasms - drug therapy | Humans | Lung Neoplasms - metabolism | Middle Aged | Pemetrexed - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Protein Kinase Inhibitors - adverse effects | Tumor Suppressor Protein p53 - genetics | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Pemetrexed - pharmacology | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Biomarkers, Tumor - metabolism | Adult | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Phenylurea Compounds - pharmacokinetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Checkpoint Kinase 1 - antagonists & inhibitors | Tumor Suppressor Protein p53 - metabolism | Phenylurea Compounds - therapeutic use | Treatment Outcome | Pemetrexed - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Biomarkers, Tumor - genetics | Phenylurea Compounds - pharmacology | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Pyrazines - pharmacology | Complications and side effects | Care and treatment | Usage | Analysis | Clinical trials | Research | Metastasis | Lung cancer, Non-small cell | Risk factors
Journal Article
Expert Opinion on Drug Metabolism & Toxicology, ISSN 1742-5255, 07/2011, Volume 7, Issue 7, pp. 919 - 928
Introduction: Pemetrexed is a multi-targeted antifolate cytotoxic agent that has demonstrated activity in a number of very common cancer types including NSCLC... 
pemetrexed | CNS distribution | NSAID | antimetabolite | pharmacokinetic | third-space fluid | renal impairment | ADVANCED SOLID TUMORS | EVERY 21 DAYS | MULTITARGETED ANTIFOLATE MTA | BIOCHEMISTRY & MOLECULAR BIOLOGY | BODY-SURFACE AREA | CONTINUAL REASSESSMENT METHOD | PHASE-I EVALUATION | MALIGNANT PLEURAL MESOTHELIOMA | FOLIC-ACID | CELL LUNG-CANCER | METASTATIC BREAST-CANCER | PHARMACOLOGY & PHARMACY | Folic Acid Antagonists - administration & dosage | Guanine - analogs & derivatives | Humans | Drug Evaluation | Antineoplastic Agents - administration & dosage | Platinum Compounds - pharmacokinetics | Tissue Distribution | Drug Interactions | Liver - drug effects | Antineoplastic Agents - pharmacokinetics | Folic Acid Antagonists - pharmacokinetics | Disease Models, Animal | Guanine - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols | Glutamates - pharmacokinetics | Pemetrexed | Mesothelioma - drug therapy | Brain - drug effects | Vitamins - pharmacokinetics | Animals | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics | Glutamates - administration & dosage | Carcinoma, Non-Small-Cell Lung - drug therapy | Platinum Compounds - administration & dosage | Kidney Neoplasms - drug therapy | Vitamins - administration & dosage | Guanine - administration & dosage
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 4/2013, Volume 112, Issue 2, pp. 247 - 255
Brain metastases (BM) and leptomeningeal metastases (LM) are devastating neurologic complications. Pemetrexed is a multi-targeted anti-folate agent approved... 
Neurology | Medicine & Public Health | Oncology | Brain metastases | Pharmacokinetics | Leptomeningeal metastases | Pemetrexed | ADVANCED BREAST-CANCER | MANAGEMENT | DOSE INTRAVENOUS METHOTREXATE | CHEMOTHERAPY | CLINICAL NEUROLOGY | TEMOZOLOMIDE | CELL LUNG-CANCER | PHASE-II TRIAL | ONCOLOGY | TOPOTECAN | CLINICAL-PRACTICE GUIDELINE | NEOPLASTIC MENINGITIS | Glutamates - therapeutic use | Prognosis | Antimetabolites, Antineoplastic - pharmacokinetics | Follow-Up Studies | Guanine - analogs & derivatives | Humans | Middle Aged | Glutamates - cerebrospinal fluid | Neoplasm Recurrence, Local - drug therapy | Neoplasm Recurrence, Local - mortality | Neoplasm Recurrence, Local - pathology | Tissue Distribution | Guanine - cerebrospinal fluid | Brain Neoplasms - secondary | Antimetabolites, Antineoplastic - blood | Meningeal Neoplasms - drug therapy | Adult | Female | Glutamates - blood | Brain Neoplasms - mortality | Guanine - therapeutic use | Guanine - pharmacokinetics | Neoplasms - mortality | Glutamates - pharmacokinetics | Survival Rate | Brain Neoplasms - drug therapy | Disease Progression | Meningeal Neoplasms - mortality | Neoplasms - drug therapy | Antimetabolites, Antineoplastic - cerebrospinal fluid | Antimetabolites, Antineoplastic - therapeutic use | Guanine - blood | Pilot Projects | Aged | Neoplasm Staging | Neoplasms - pathology | Meningeal Neoplasms - secondary | Complications and side effects | Care and treatment | Chemotherapy | Development and progression | Metastasis | Methotrexate | Lung cancer, Non-small cell | Folic acid | Cancer | Index Medicus
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2014, Volume 32, Issue 5, pp. 955 - 968
LY2603618 is an inhibitor of checkpoint kinase 1 (CHK1), an important regulator of the DNA damage checkpoints. Preclinical experiments analyzed NCI-H2122 and... 
Medicine & Public Health | CHK1 | Lung cancer | Cell cycle | Oncology | LY2603618 | Pharmacology/Toxicology | Pharmacokinetics | Cancer | PLUS CISPLATIN | DNA-DAMAGE | DEPENDENT KINASE INHIBITOR | ANTITUMOR-ACTIVITY | FLUOROURACIL | GEMCITABINE | CELL LUNG-CANCER | CHECKPOINT KINASE-1 | ONCOLOGY | ABROGATION | PHARMACOLOGY & PHARMACY | Cisplatin - pharmacokinetics | Glutamates - adverse effects | Antineoplastic Combined Chemotherapy Protocols - blood | Guanine - analogs & derivatives | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cisplatin - administration & dosage | Neoplasms - blood | Phenylurea Compounds - adverse effects | Adult | Cisplatin - blood | Female | Glutamates - blood | Guanine - adverse effects | Phenylurea Compounds - pharmacokinetics | Guanine - pharmacokinetics | Glutamates - pharmacokinetics | Phenylurea Compounds - blood | DNA - metabolism | Pemetrexed | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Guanine - blood | Animals | Phenylurea Compounds - administration & dosage | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Cell Line, Tumor | Cisplatin - adverse effects | Glutamates - administration & dosage | Aged | Neoplasms - pathology | Pyrazines - blood | Guanine - administration & dosage | Complications and side effects | DNA damage | Development and progression | Research | Risk factors | Studies | Pharmacology | Inhibitor drugs | Cancer therapies | Analysis | Reaction kinetics | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2010, Volume 16, Issue 10, pp. 2872 - 2880
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 10/2014, Volume 9, Issue 10, pp. e109892 - e109892
Journal Article
Cancer Research, ISSN 0008-5472, 07/2011, Volume 71, Issue 14, pp. 4955 - 4967
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 8/2011, Volume 68, Issue 2, pp. 531 - 538
Leptomeningeal carcinomatosis is a devastating complication of malignant disease. In this study, we evaluated the safety and pharmacokinetics of intrathecally... 
Medicine & Public Health | Toxicity | Cancer Research | Oncology | Pharmacology/Toxicology | Pharmacokinetics | Pemetrexed | Leptomeningeal carcinomatosis | SOLID TUMORS | METHOTREXATE | MULTITARGETED ANTIFOLATE | ANTITUMOR-ACTIVITY | CANCER | LY231514 | NEURONAL DEGENERATION | MENINGEAL CARCINOMATOSIS | ONCOLOGY | LEPTOMENINGEAL METASTASES | PHARMACOLOGY & PHARMACY | BRAIN | Neurons - pathology | Antimetabolites, Antineoplastic - pharmacokinetics | Glutamates - adverse effects | Guanine - analogs & derivatives | Half-Life | Male | Metabolic Clearance Rate | Chromatography, High Pressure Liquid | Antimetabolites, Antineoplastic - administration & dosage | Dose-Response Relationship, Drug | Tissue Distribution | Tandem Mass Spectrometry | Neurotoxicity Syndromes - pathology | Neurotoxicity Syndromes - blood | Guanine - analysis | Guanine - adverse effects | Drug Evaluation, Preclinical | Neurons - drug effects | Catheters, Indwelling | Injections, Spinal | Subarachnoid Space | Antimetabolites, Antineoplastic - analysis | Guanine - pharmacokinetics | Rats | Glutamates - pharmacokinetics | Rats, Sprague-Dawley | No-Observed-Adverse-Effect Level | Animals | Antimetabolites, Antineoplastic - adverse effects | Glutamates - administration & dosage | Glutamates - analysis | Toxicity Tests | Guanine - administration & dosage | Neurotoxicity Syndromes - cerebrospinal fluid | Antimitotic agents | Primates | Medical colleges | Evaluation | Safety and security measures | Antineoplastic agents | Index Medicus
Journal Article